U.K.-based biotech Alchemab on Tuesday announced a licensing agreement with Eli Lilly (NYSE:LLY) to jointly develop ATLX-1282, an early-stage therapeutic candidate targeting amyotrophic lateral ...

Eli Lilly is licensing rights to a Phase 1-ready antibody that startup Alchemab developed for amyotrophic lateral sclerosis and other neurodegenerative disorders. Lilly’s pipeline has ALS drug ...

Lilly will pay up to $415 million in an unspecified combination of upfront, discovery milestones and royalties for ATLX-1282, Alchemab's first-in-class preclinical program for amyotrophic lateral ...

Under the terms of the agreement, Lilly will pay Alchemab up to $415 million, which includes an undisclosed upfront payment as well as discovery, development, commercialization, and potential royalty ...

Alchemab's Chief Executive Officer, Jane Osbourn, commented: "As the first programme from our highly novel platform, this is a landmark transaction for Alchemab. With Lilly's deep expertise in ...

Alchemab's chief executive, Jane Osbourn, said the Lilly deal is a "landmark transaction" for the company, adding: "With Lilly's deep expertise in neurological conditions, they are ideally placed ...

- New agreement with Lilly to license ATLX-1282, a first-in-class IND-ready programme for neurodegenerative conditions targeting a novel receptor and mechanism ...

Eli Lilly will be licensing Alchemab Therapeutics’ preclinical programme for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases in a deal worth up to $415m. The agreement, ...

UK-based Alchemab has secured a licensing agreement worth up to $415m with Eli Lilly for ATLX-1282, its investigational antibody therapy targeting amyotrophic lateral sclerosis (ALS) and other ...

Alchemab's Chief Executive Officer, Jane Osbourn, commented: "As the first programme from our highly novel platform, this is a landmark transaction for Alchemab. With Lilly's deep expertise in ...

U.K.-based biotech Alchemab on Tuesday announced a licensing agreement with Eli Lilly (NYSE:LLY) to jointly develop ATLX-1282, an early-stage therapeutic candidate targeting amyotrophic lateral ...